FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

New Delhi: Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory.

In a social media post on Thursday, FSSAI observed “serious non-compliances” during the inspection of the manufacturing unit in Punjab.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

Related Posts

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore